AR126178A1 - Compuesto, antagonista del receptor de endotelina a y composición farmacéutica - Google Patents
Compuesto, antagonista del receptor de endotelina a y composición farmacéuticaInfo
- Publication number
- AR126178A1 AR126178A1 ARP220101606A ARP220101606A AR126178A1 AR 126178 A1 AR126178 A1 AR 126178A1 AR P220101606 A ARP220101606 A AR P220101606A AR P220101606 A ARP220101606 A AR P220101606A AR 126178 A1 AR126178 A1 AR 126178A1
- Authority
- AR
- Argentina
- Prior art keywords
- endothelin
- alkyl
- receptor
- compound
- haloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229940121889 Endothelin A receptor antagonist Drugs 0.000 title abstract 2
- 239000003062 endothelin A receptor antagonist Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 102000017914 EDNRA Human genes 0.000 abstract 3
- 108010090549 Endothelin A Receptor Proteins 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 102000017930 EDNRB Human genes 0.000 abstract 1
- 108010090557 Endothelin B Receptor Proteins 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- -1 respectively Chemical compound 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un objeto de la presente invención es proporcionar un compuesto que tenga un efecto antagonista del receptor ETA, etc. El objeto puede lograrse mediante un compuesto representado por la fórmula (1) en donde las variables son como se describen en este documento, o una sal farmacéuticamente aceptable del mismo. Reivindicación 1: Un compuesto representado por la fórmula (1) caracterizado porque R¹ y R² son cada uno independientemente hidrógeno o alquilo, R³ y R⁴ son cada uno independientemente hidrógeno o alquilo, o R³ y R⁴ juntos forman oxo, R⁵ a R⁷ son cada uno independientemente hidrógeno, alquilo, haloalquilo, halógeno, alcoxi o haloalcoxi, cada R⁸ es independientemente alquilo, haloalquilo o halógeno, n es un número entero de 0 a 3, y Ar está representado por la fórmula (Ar1) o (Ar2) en donde X e Y son nitrógeno y oxígeno, respectivamente, u oxígeno y nitrógeno, respectivamente, R⁹ y R¹⁰ son cada uno independientemente hidrógeno, alquilo, haloalquilo o halógeno, cada R¹¹ es independientemente alquilo, haloalquilo, halógeno, alcoxi o haloalcoxi, y m es un número entero de 0 a 3, o una sal farmacéuticamente aceptable del mismo. Reivindicación 13: Un antagonista del receptor de endotelina A caracterizado porque comprende el compuesto o la sal farmacéuticamente aceptable del mismo de acuerdo a una cualquiera de las reivindicaciones 1 a 12. Reivindicación 14: El antagonista del receptor de endotelina A de acuerdo a la reivindicación 13, caracterizado porque el antagonista del receptor de endotelina A inhibe selectivamente un receptor de endotelina A en contraste con un receptor de endotelina B.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103047 | 2021-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126178A1 true AR126178A1 (es) | 2023-09-27 |
Family
ID=84545734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101606A AR126178A1 (es) | 2021-06-22 | 2022-06-21 | Compuesto, antagonista del receptor de endotelina a y composición farmacéutica |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4361146A1 (es) |
| JP (1) | JPWO2022270487A1 (es) |
| KR (1) | KR20240022646A (es) |
| CN (1) | CN117255791A (es) |
| AR (1) | AR126178A1 (es) |
| AU (1) | AU2022297082B2 (es) |
| BR (1) | BR112023019460A2 (es) |
| CA (1) | CA3217189A1 (es) |
| IL (1) | IL306095A (es) |
| TW (1) | TW202317555A (es) |
| WO (1) | WO2022270487A1 (es) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5514696A (en) | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| CZ299246B6 (cs) | 1995-04-04 | 2008-05-28 | Encysive Pharmaceuticals Inc. | Sulfonamid, farmaceutická kompozice s jeho obsahem a jeho použití pro výrobu léciva |
| UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| WO1998033781A1 (en) | 1997-01-30 | 1998-08-06 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| EE04156B1 (et) | 1997-04-28 | 2003-10-15 | Texas Biotechnology Corporation | Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks |
| AU2464301A (en) * | 1999-12-31 | 2001-07-16 | Encysive Pharmaceuticals Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| GB0223854D0 (en) | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| MX358151B (es) | 2012-01-31 | 2018-08-07 | Eisai R&D Man Co Ltd | Derivado de sitaxentan. |
| US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
-
2022
- 2022-06-21 KR KR1020247002106A patent/KR20240022646A/ko unknown
- 2022-06-21 AU AU2022297082A patent/AU2022297082B2/en active Active
- 2022-06-21 EP EP22828404.8A patent/EP4361146A1/en active Pending
- 2022-06-21 BR BR112023019460A patent/BR112023019460A2/pt unknown
- 2022-06-21 WO PCT/JP2022/024638 patent/WO2022270487A1/ja active Application Filing
- 2022-06-21 CN CN202280032424.9A patent/CN117255791A/zh active Pending
- 2022-06-21 AR ARP220101606A patent/AR126178A1/es unknown
- 2022-06-21 JP JP2023530474A patent/JPWO2022270487A1/ja active Pending
- 2022-06-21 TW TW111122976A patent/TW202317555A/zh unknown
- 2022-06-21 CA CA3217189A patent/CA3217189A1/en active Pending
- 2022-06-21 IL IL306095A patent/IL306095A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022297082A1 (en) | 2023-09-28 |
| IL306095A (en) | 2023-11-01 |
| TW202317555A (zh) | 2023-05-01 |
| AU2022297082B2 (en) | 2024-04-18 |
| EP4361146A1 (en) | 2024-05-01 |
| KR20240022646A (ko) | 2024-02-20 |
| CN117255791A (zh) | 2023-12-19 |
| JPWO2022270487A1 (es) | 2022-12-29 |
| BR112023019460A2 (pt) | 2024-01-23 |
| CA3217189A1 (en) | 2022-12-29 |
| WO2022270487A1 (ja) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| PE20210004A1 (es) | Inhibidores de mcl-1 | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR099788A1 (es) | Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih | |
| AR109424A2 (es) | Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteína quinasa akt | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR049333A1 (es) | Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas. | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR116913A1 (es) | Inhibidores de apol1 y sus métodos de uso | |
| AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| AR111814A1 (es) | Compuestos de formimidamida útiles contra microorganismos fitopatógenos | |
| AR120982A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre | |
| AR115936A1 (es) | Compuestos útiles en terapia del vih | |
| AR120377A1 (es) | Derivados heteroaromáticos de sulfiliminas o sulfoximinas con actividad fungicida | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh | |
| AR126178A1 (es) | Compuesto, antagonista del receptor de endotelina a y composición farmacéutica | |
| AR093281A1 (es) | Benzotiazoles ligados a amida, urea o sulfonamida como inhibidores de la lipasa endotelial | |
| AR122517A1 (es) | Isoxazolidinas como inhibidores de ripk1 y usos de las mismas | |
| AR111282A1 (es) | Inhibidores de cdpk1 ii, composiciones y métodos relacionados con los mismos |